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Reactivation ofMycobacterium tuberculosis can occur in patients with latent tuberculosis (TB)
with risk factors including chronic disease (i.e., malignancy). We herein describe the case of
an immigrant from Hong Kong with lung cancer and no known TB disease who presents
with reactivation of TB in the setting of chemotherapy and radiation therapy.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Clinical practice points
• Tuberculosis (TB) reactivation occurs in immunosup-
pressed individuals.
• Both the Centers for Disease Control and Prevention and
American Thoracic Society recognize that cancer is a risk
factor for developing TB.
• Doublet platinum-based chemotherapy is the mainstay of
treatment for nonsmall cell lung cancer.
• Radiation therapy affects both healthy, viable tissue and
malignant cells.• Combined chemotherapy and radiation therapy can
elevate the risk for developing infections.
Case report
A 61-year-old Cantonese-speaking man from Hong Kong
presented with a productive cough and fever of 3 weeks dura-
tion. He had a history of Stage IIIA squamous-cell carcinoma
of the right lung with mediastinal lymph node involvement
that was diagnosed 6 months prior to this admission. He0016, USA.
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cisplatin and gemcitabine 2 months prior to admission.
Follow-up chest computed tomography (CT) imaging showed
extensive air-space consolidation that was contiguous with
an obstructing right upper lobe tumor. A restaging positron
emission tomography-CT showed a right upper lobe tumor
measuring 2.2 · 2.2 cm2 and a concomitant consolidation in
that lobe. He was evaluated by thoracic surgery for a possible
surgical resection; however, the therapeutic benefit was low
given the extent of his disease. Therefore, his treatment
regimen was changed to three cycles of docetaxel and
carboplatin with concomitant radiation therapy at a dose of
5940 cGy over 33 fractions to the right lung, which he
completed 7 weeks prior to admission. His Karnofsky
performance score was 80 throughout his course with an
Eastern Cooperative Oncology Group performance status of 1.
On this presentation, he was evaluated by his primary care
physician who noted a new leukocytosis and a cavitation at
the site of his cancer with communication to the right upper
lobe bronchus on CT imaging (Fig. 1). The patient was started
on broad-spectrum intravenous antibiotics for the possibility
of a bacterial pneumonia with abscess formation; however,
his symptoms did not resolve. Acid-fast bacilli (AFB) staining
results were positive. He was started on rifampin, isoniazid,
pyrazinamide, and ethambutol (RIPE therapy) as an outpa-
tient. His AFB culture eventually returned positive for
Mycobacterium tuberculosis and a DNA probe completed by
the Department of Health confirmed this diagnosis. He was
admitted to the hospital after continued cough, which was
now associated with weight loss. In addition, he has an
8-month-old grandchild in the home and had no ability to
self-isolate. He was continued on RIPE therapy.
During the course of his hospitalization, sputum AFB sam-
ples were sent daily to the laboratory until a negative result
was obtained. After 30 days, he was eventually discharged
home to continue on isoniazid, rifampin, and pyrazinamide.
In the setting of active tuberculosis (TB) and concomitant lung
cancer, he was started on a less-aggressive chemotherapy
regimen with weekly vinorelbine; however, despite this his
cancer has progressed. He is currently being considered for
a clinical trial.Fig. 1 – (A) Axial contrast-enhanced computed tomography (CT)
‘drowned lung’ due to atelectasis and bronchial tumor obstruct
window.Written informed consent was obtained from the patient
(available upon request).
Discussion
TB management has changed very little in the past four dec-
ades. In the United States, screening for latent TB has been a
crucial part in the control of TB. Both the Centers for Disease
Control and Prevention (CDC) and the American Thoracic
Society (ATS) have recognized for over four decades that can-
cer is a recognizable risk factor for the development of TB [1].
The 2000 ATS guidelines for targeted tuberculin testing and
latent TB treatment list the following as oncologic risk factors
for the development of active TB: leukemia, lymphoma, and
carcinomas of the head and neck [1]. The purported mecha-
nism of action suggests a reduction in local infection barriers
at the site of cancer and/or increased susceptibility due to
immunosuppression, thereby leading to the inability to fight
infection [2]. Although it is recognized that hematologic
malignancies increase the risk of developing active TB, the
link between solid-organ malignancies and developing TB is
less known. A case series of patients with cancer at a tertiary
hospital in South Korea showed that those patients with
solid-organ malignancy had a 4.7 times greater risk of
developing active TB compared with those patients without
malignancy [3,4]. A case series in multiple hospitals in Japan
in 1990 involving 445 cases showed that various types of
solid-organ malignancies placed patients at risk for active
TB and that the introduction of chemotherapeutic agents
increased the risk of TB progression [5]. Over a 10-year span
at the MD Anderson Cancer Center, only 30 cases of active
TB were identified in non-human immunodeficiency virus-
infected patients, with most found in patients born outside of
the United States [6]. Of those 30 patients, the ones receiving
higher doses of chronic corticosteroid therapy fared worse
and had a greater mortality than those receiving intermittent,
cyclic systemic chemotherapy. By contrast, a case series at
Memorial Sloan-Kettering in New York City revealed no asso-
ciation between active TB and solid-organ malignancy [7]. At
this point, the patient-level response of active (or latent) TB to
antitubercular combination treatment is not well described indemonstrates obliteration of the right upper lobe with
ion of the bronchus, mediastinal window, and (B) lung
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described in case series.
Two-drug platinum-based chemotherapy is the standard
of care for nonsmall cell lung carcinoma, which has shown
a survival benefit in multiple clinical trials in addition to best
supportive care [8–14]. Our patient was initially started on
combination cytotoxic chemotherapy with cisplatin and
gemcitabine, and subsequently transitioned to second-line
therapy with carboplatin and docetaxel. Cisplatin and
carboplatin are platinum chemotherapeutic agents that work
by inhibiting DNA synthesis by interrupting the crosslinking
of the DNA helix [15]. Docetaxel works by inhibiting the
depolymerization of tubulin thereby inhibiting DNA, RNA,
and protein synthesis [16]. The ionizing effect of radiation
therapy works by directly damaging the DNA of cancer cells
(and normal cells). Our patient had no symptoms of active
TB between the first- and second-line doublet chemotherapy
regimens. Platinum-based chemotherapeutic agents have
radiosensitizing effects that provide better tumoricidal effects
when used concomitantly [17–19]. Although no cases of active
TB caused by platinum chemotherapeutic agents, gemcitabine,
or docetaxel have been reported, there have been cases of
reactivation TB reported in patients undergoing radiation
therapy [20]. In our patient, we theorize that he most likely
had previous latent TB, especially given his higher risk of
acquiring TB (i.e., TB-endemic country of origin). There was
also an additive effect whereby the systemic toxicity of the
chemotherapy in combination with the ‘‘spatial deposition
of radioactive energy’’ to both malignant and normal cells
led to cancer cell death, the clinical benefit we strive for in
treating any malignancy [21]. However, the absence of selec-
tivity of the combined effects does have drawbacks, affecting
both healthy, viable tissue and malignant cells, which can
affect chemotherapy drug delivery [21]. The effect of radiation
on the immune system is thought to involve multiple factors:
(a) local tissue damage, which inhibits the body’s reaction to
infection; (b) peripheral depletion of lymphocytes, thus blunting
the systemic immune response; and (c) an alteration in the
immune cellular balance, namely, B cells, T cells, and natural
killer cells [22–24]. The combination of immune-suppressing
chemotherapy in the setting of radiation therapy elevates
the risk of primary infections and reactivation of chronic
and indolent infections in this patient population.Conclusion
Little is known about the link between solid-organ
malignancy and TB. Reported case series from large academic
cancer centers have had conflicting results in patients with
solid-organ malignancies. Our patient had squamous-cell
carcinoma of the lung and was started on first-line doublet
platinum-based chemotherapy before transitioning to
second-line chemotherapy with concurrent radiation therapy.
He subsequently developed active TB. Given the likelihood of
underlying latent TB in this patient prior to the initiation of
cancer therapy, he developed active TB likely due to both local
tissue and systemic immune factors, thus allowing for this
indolent, inactive infection to avoid the natural checks and
balances to keep it under control. This case highlights thelack of widely acceptable and established standards for both
screening for latent TB and treatment of active TB in patients
undergoing treatment for active solid-organ malignancy. We
strongly recommend screening all patients born in countries
with endemic TB with either a tuberculin skin test (also
known as a ‘‘purified protein derivative test’’) or with an
interferon-gamma release assay from whole blood to rule
out latent TB before beginning radiotherapy or chemotherapy
for solid-tumor malignancy. With proper and standardized
screening efforts prior to beginning treatment for malignancy,
reactivation of TB could effectively be eliminated. Further
research is needed to help guide the oncology and
pulmonology fields in the management of this special patient
population.Conflicts of interest
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